CanSino Biologics Inc.
CanSino Biologics Inc. (CASBF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
casbf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CanSino Biologics Inc. (CASBF) measures how much investors pay for each dollar of the company's trailing earnings. CASBF's current PE ratio of N/A is calculated by dividing its stock price of $3.97 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CanSino Biologics Inc.You CASBF | $1.4B | N/A | — | -$0.00 |
 Aspen Pharmacare Holdings Limited APNHY | $4.0B | N/A | — | -$2.44 |
 Fagron N.V. ARSUF | $2.0B | 16.06x | +3.1% | $1.25 |
 China Medical System Holdings Limited CHSYF | $2.3B | 15.75x | +1.1% | $0.60 |
 Curaleaf Holdings, Inc. CURLF | $3.0B | N/A | — | -$0.93 |
 Dermapharm Holding SE DMPHF | $2.9B | 13.70x | -12.1% | $2.46 |
 Hisamitsu Pharmaceutical Co., Inc. HTSUF | $2.0B | 16.80x | +7.8% | $269.34 |
Industry Average 4 peers with valid PE | — | 15.58x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 309.29x | $0.11 | — | |
2024-12-31 FY2024 | — | $-1.53 | — | |
2023-12-31 FY2023 | — | $-6.01 | — | |
2022-12-31 FY2022 | — | $-3.69 | — | |
2021-12-31 FY2021 | 18.88x | $7.74 | — | |
2020-12-31 FY2020 | — | $-1.60 | — | |
2019-12-31 FY2019 | — | $-0.63 | — | |
2018-12-31 FY2018 | — | $-0.88 | — | |
2017-12-31 FY2017 | — | $-0.30 | — | |
2016-12-31 FY2016 | — | $-0.23 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CanSino Biologics Inc. (CASBF) measures how much investors pay for each dollar of the company's trailing earnings. CASBF's current PE ratio of N/A is calculated by dividing its stock price of $3.97 by its TTM earnings per share of -$0.00.
Frequently asked questions
CASBF pe ratio · 6 questionsCASBF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.97 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via CASBF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CanSino Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08